UK markets closed
  • FTSE 100

    -20.90 (-0.28%)
  • FTSE 250

    -215.15 (-0.94%)
  • AIM

    -11.87 (-1.01%)

    +0.0011 (+0.09%)

    -0.0030 (-0.22%)

    -453.12 (-1.42%)
  • CMC Crypto 200

    +12.03 (+1.17%)
  • S&P 500

    +3.82 (+0.08%)
  • DOW

    -201.79 (-0.56%)

    +2.15 (+2.62%)

    -4.10 (-0.23%)
  • NIKKEI 225

    -364.82 (-1.28%)

    -46.48 (-0.19%)
  • DAX

    -148.36 (-0.93%)
  • CAC 40

    -58.14 (-0.81%)

Global TROP2 Antibody Market & Clinical Trials Report 2021-2026 - Ongoing Clinical Trials Assessment by Status, Phase & Region

·5-min read

Dublin, Dec. 21, 2021 (GLOBE NEWSWIRE) -- The "Global TROP2 Antibody Market & Clinical Trials Insight 2026" report has been added to's offering.

The global Trop2 targeting drug market is expected to surpass US$ 4 Billion by 2026

Surge in prevalence of cancer across geographies, high demand for targeted therapeutics for cancer treatment, favorable reimbursement policies offered by manufacturers and insurance providers, and rise in awareness of Trop-2 targeting drug owing o high efficiency will propel the growth of market.

In addition, surge in geriatric population and increase in technological advancements in screening & diagnosis of cancer supplement the market growth.

The key players in the TROP2 Antibody market include Daiichi Sankyo, Immunomedics, Gilead Sciences, AstraZeneca, Pfizer, BioThera Solution, and others. The major players in the market have adopted strategic alliances such as collaboration, partnerships, or joint ventures to cope up with the high cost of research and development and to maintain their share in market.

For instance, Daiichi Sankyo and AstraZeneca have recently announced second trial collaboration with Merck to evaluate the combination of datopotamab deruxtecan (Dato-DXd), a TROP2 directed DXd antibody drug conjugate (ADC) and Keytruda in non-small cell lung cancer patients.

Studies have also demonstrated that Trop2 is highly expressed on several cancer cells and is generally associated with its aggressive nature. Apart from this, it is also involved in several signaling pathways which ultimately lead to cancer cell growth and proliferation. Therefore, targeting Trop2 can be an alternative to target cancer.

Recently, scientists developed novel antibody drug conjugate in which the therapeutic antibody is targeted towards Trop2, thereby delivering the cytotoxin to the surface of tumor cell. Sacituzumab govitecan-hziy (Trodelvy) developed by Immunomedics is the first trop2 targeted antibody drug conjugate which has been approved for patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease.

The introduction of Trodelvy in 2020 is expected to witness high growth rates in market due to lack of effective targeted therapies in mTNBC. It is believed that Trodelvy will revolutionize the overall treatment of TNBC and will significantly improve the survival outcomes.

Beyond the approval of Trodelvy in US, it has also gained approval in Australia, Canada, UK, and Switzerland for adults with metastatic TNBC. Apart from this, the drug is present in regulatory view in other regions including Europe, China and Singapore.

Recently, European Medicines Agency has recommended the marketing of Trodelvy, indicating that the drug will enter the market in coming months. The rapid approval of drug in different regions will fuel the growth of market in coming years.

The quick approval of Trodelvy has further empowered innovation and development in this sector. To date, a cocktail of Trop2 targeted drugs including DS-1062a, RN927C, BAT8003, SKB264, JS108 are present in clinical development.

These drugs have been designed to target a wide range of cancer including non-small cell lung cancer, epithelial cancer, skin cancer, colon cancer, and others.

Apart from this, several investigational studies are also ongoing to evaluate the efficacy of Trodelvy for the treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer and metastatic non-small cell lung cancer. Additional evaluation across multiple solid tumors is also underway. The forthcoming years will see rapid influx of Trop-2 targeted therapies in wide range of cancers.

Global TROP2 Antibody Market & Clinical Trials Insight 2026 Report Analysis and Data Highlights:

  • Research Methodology

  • Global & Regional Market Analysis

  • Global TROP2 Antibody Market Opportunity Assessment: > USD 4 Billion

  • Market and Drug Sales Insight 2020 Till 2026

  • Approved Drug In Market: 1 Drugs

  • Approved TROP2 Antibody Patent, Price and Sales insight 2020 Till 2026

  • Future Market Assessment By Indication Till 2026

  • Ongoing Clinical Trials Assessment by Status, Phase & Region

  • Key Market Dynamics

  • Competitor Landscape

Key Topics Covered:

1. Introduction to TROP2 Targeting Therapy Market
1.1 Overview
1.2 History of TROP2 Targeting Therapeutics

2. TROP2 Ideal Clinical Biomarker for Cancer

3. TROP2 Targeting Therapeutics Mechanism

4. Global TROP2 Targeting Therapy Market Analysis
4.1 Current Market Scenario
4.2 Future Market Opportunity

5. Global TROP2 Targeting Therapy Market Opportunity by Region
5.1 US
5.2 Europe
5.3 Japan
5.4 Rest of World

6. Global TROP2 Targeting Therapy Market by Cancer
6.1 Breast Cancer
6.2 Urothelial Carcinoma
6.3 Lung Cancer
6.4 Pancreatic Cancer
6.5 Prostate Cancer

7. First Approved TRO2 Targeting Antibody - Trodelvy (Sacituzumab Govitecan)
7.1 Overview
7.2 Approval, Patent & Exclusivity

8. Trodelvy - Commercial Information
8.1 Dosage & Price Analysis
8.2 Sales Analysis

9. Trodelvy Sales Forecast 2026

10. TROP2 Targeted Therapy Clinical Trials Insight
10.1 By Phase
10.2 By Development Status
10.3 By Region

11. Global TROP2 Targeting Therapy Market - Ongoing Research & Development
11.1 Datopotamab Deruxtecan (DS-1062)
11.2 SKB264
11.3 JS108
11.4 BAT 8003
11.5 Trodelvy (Sacituzumab Govitecan)

12. Global TROP2 Targeted Therapy Market Dynamics
12.1 Market Drivers
12.2 Market Challenges

13. Global TROP2 Targeting Therapy Market Future Outlook

14. Competitive Landscape
14.1 Amunix
14.2 ARIUS Research
14.3 AstraZeneca
14.4 Biothera
14.5 Daiichi Sankyo Company
14.6 Gilead
14.7 Immunomedics
14.8 Janux Therapy
14.9 Klus Pharma
14.10 Myeloid therapeutics
14.11 Pfizer Inc
14.12 Shanghai Junshi Bioscience

For more information about this report visit

CONTACT: CONTACT: Laura Wood, Senior Press Manager For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting